CADL Candel Therapeutics, Inc.
Healthcare$7.95-0.50%ClosedMarket Cap: $436.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.59
P/S
0.00
EV/EBITDA
-4.84
DCF Value
$2.20
FCF Yield
-11.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-60.4%
ROA
-27.0%
ROIC
-28.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-16.3M | $-8.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-15.8M | $-29.5M | $— | — |
| FY null | $0.00 | NaN% | $-48.3M | $-38.2M | $— | — |
| Q3 null | $0.00 | NaN% | $-13.2M | $-11.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-11.2M | $-4.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-8.1M | $7.4M | $— | — |
| Q4 null | $0.00 | NaN% | $-8.1M | $-14.1M | $— | — |
| FY null | $0.00 | NaN% | $-33.4M | $-55.2M | $— | — |
| Q3 null | $0.00 | NaN% | $-8.8M | $-10.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-8.6M | $-22.2M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-7.9M | $-8.2M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-10.3M | $-11.1M | $-0.38 | — |